Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

Core Viewpoint - Tango Therapeutics announces the retirement of founding CEO Dr. Barbara Weber, who will transition to Executive Chair, while Dr. Malte Peters is appointed as President and CEO, effective immediately [1][2][3] Leadership Transition - Dr. Barbara Weber will support the senior management team and work with Dr. Peters to ensure a smooth transition and continued clinical execution throughout 2026 [2] - Alexis Borisy will move from Board Chair to Lead Independent Director [2] Achievements and Future Direction - Dr. Weber expressed pride in the company's accomplishments over the past eight years, particularly in advancing vopimetostat into its first registrational trial [3] - Dr. Peters brings extensive experience in clinical development and leadership, having previously served as Chief Research and Development Officer at MorphoSys AG and held key positions at Novartis [3] Clinical Milestones - The company has renewed its guidance on anticipated clinical milestones for 2026, including combination trials with vopimetostat and daraxonrasib, as well as vopimetostat and zoldonrasib, with initial safety and efficacy data expected in 2026 [4] - Upcoming pivotal studies include vopimetostat monotherapy for second-line pancreatic cancer and TNG456 monotherapy phase 1/2 trial [6]